抗體 > 重組抗體 > SARS-CoV-2 Spike RBD Nanobody
  • 產品名稱:

    SARS-CoV-2 Spike RBD Nanobody

  • 英文名稱:

    SARS-CoV-2 Spike RBD Nanobody

  • 貨號:
    CSB-RA33245A2GMY
  • 規格:
    ¥4,800
  • 別名:
    Anti-coronavirus spike Antibody; Anti-cov spike Antibody; Anti-ncov RBD Antibody; Anti-ncov S1 Antibody;Anti-ncov spike Antibody; Anti-novel coronavirus RBD Antibody; Anti-novel coronavirus S1 Antibody; Anti-novel coronavirus spike Antibody; Anti-RBD Antibody; Anti-S1 Antibody; Anti-Spike RBD Antibody; E2 Antibody; E2 glycoprotein Antibody; Human coronavirus spike glycoprotein Antibody; S Antibody; SARS-CoV-2 S1 RBD Antibody; S glycoprotein Antibody; Spike glycoprotein Antibody
  • 種屬:
    Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)
  • 免疫原:
    Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa) (CSB-YP3324GMY1 and CSB-MP3324GMY1b1)
  • 種屬反應性:
    Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)
  • 應用范圍:
    ELISA, GICA, Neutralising; Recommended dilution: ELISA:1:10000-1:100000, GICA:1:10000-1:40000, Neutralising:1:100-1:10000
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    VHH fusion with human IgG1 Fc
  • 純化方式:
    Affinity-chromatography
  • 標記方式:
    Non-conjugated
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
  • 產品提供形式:
    Liquid
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 圖片:

     


    The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD

    Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) at 2 μg/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml.



    In the Colloidal Gold Immunochromatography Assay

    detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.



    Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited by SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) with the ICC50 is 1.296 nM.



    Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited by SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) with the IC50 is 0.1074 μg/ml.

  • 說明書:

    注:產品說明書可能有改進,請直接與CUSABIO產品專員聯系,索取最新版說明書!

  • Accession No.:
  • 指標名稱:
    S (Spike glycoprotein)
  • 研究領域:
    Microbiology
  • 克隆號:
    A1
  • 產品描述:
    This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/ml IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.